文献速递浆细胞疾病造血干细胞移植与细胞治疗

复发或难治性多发性骨髓瘤的标准治疗伊基奥仑赛

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

该研究基于国际血液与骨髓移植研究中心登记组数据,评估821例接受标准治疗伊基奥仑赛的复发或难治性多发性骨髓瘤患者,中位随访11.6个月,总缓解率73%,完全缓解率25%,中位无进展生存期8.8个月,细胞因子释放综合征80%、严重感染45%,安全性和有效性特征与临床试验所见相似。

要点

  • 标准治疗伊基奥仑赛总缓解率73%、完全缓解率25%,中位无进展生存期8.8个月。
  • 细胞因子释放综合征80%(≥3级3%),免疫效应细胞相关神经毒性综合征28%(≥3级5%)。
  • 临床显著感染45%,治疗相关死亡6%,第二原发恶性肿瘤4%(其中髓系恶性肿瘤1%)。

核心结论

  • 标准治疗伊基奥仑赛在复发或难治性多发性骨髓瘤中显示出与临床试验相似的良好安全性和有效性特征,即使77%患者合并显著合并症、许多合并症本会使其不符合KarMMa注册临床试验入组条件。

研究设计与样本

  • 利用国际血液与骨髓移植研究中心登记组开展的回顾性真实世界研究,纳入821例接受标准治疗伊基奥仑赛的复发或难治性多发性骨髓瘤患者,中位随访11.6个月。

主要发现

  • 中位年龄66岁,31%患者年龄≥70岁,15%为黑人,7%为西班牙裔,77%有≥1种显著合并症。
  • 中位既往治疗线数7线,15%既往接受B细胞成熟抗原靶向治疗,17%有髓外病变,27%有高危细胞遗传学。
  • 总缓解率73%,完全缓解率25%,中位无进展生存期8.8个月。
  • 治疗相关死亡6%,细胞因子释放综合征80%(≥3级3%),免疫效应细胞相关神经毒性综合征28%(≥3级5%),未报告帕金森综合征病例。
  • 临床显著感染45%,第二原发恶性肿瘤4%,其中髓系恶性肿瘤1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idecabtagene vicleucel (ide-cel) was the first US Food and Drug Administration-approved chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma (MM). However, because clinical trials are highly selective with stringent eligibility criteria, the objective of this study was to evaluate the safety and effectiveness of standard-of-care (SOC) ide-cel in the real world. Using the Center for International Blood and Marrow Transplant Research registry, we evaluated 821 patients who received SOC ide-cel. Median follow-up was 11.6 months. Median age was 66 years, and the cohort included 31% patients aged ≥70 years, with 15% Black and 7% Hispanic, and 77% of patients with ≥1 significant comorbidity. The median number of prior lines of therapy was 7, 15% patients previously received B-cell maturation antigen-directed therapy, 17% had extramedullary disease, and 27% had high-risk cytogenetics. Overall response rate was 73%, and complete response rate was 25%. Median progression-free survival was 8.8 months. Treatment-related mortality was reported in 6% of patients. Cytokine release syndrome was diagnosed in 80% of patients (grade ≥3, 3%). Immune effector cell-associated neurotoxicity syndrome was observed in 28% (grade ≥3, 5%), with no cases of Parkinsonism reported. Clinically significant infections were seen in 45% of patients. Second primary malignancies were reported in 4%, including 1% myeloid malignancies. This is, to our knowledge, the largest real-world study of ide-cel CAR-T therapy in patients with relapsed/refractory (R/R) MM. We observed a favorable safety and efficacy profile that mirrors trial experience, even in the setting of significant comorbidities in 77% of patients, many of which would have made them ineligible for the registrational KarMMa clinical trial. This trial was registered at www.clinicaltrials.gov as #NCT03361748.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sidana S, Ahmed N, Akhtar OS, et al. Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Blood. 2025. PMID: 40198886. doi:10.1182/blood.2024026216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。